Board of Directors
Robert A. Ingram is the Chairman of Novan’s Board of Directors and has served as a member of the Company’s Board since 2011. Since 2007, he has been a General Partner at Hatteras Venture Partners, LLC, a venture capital firm. Prior to Hatteras Venture Partners, he held the roles of Chief Executive Officer and Chairman of the Board of GlaxoWellcome until his retirement in 2009 when he became the Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline Plc. Mr. Ingram serves as Chairman of the Board for both BioCryst Pharmaceuticals, Inc. and Viamet Pharmaceuticals, Inc., a private company focused on anti-infective research. He recently retired as Chairman of the Board of Cree, Inc., having served on its board for 10 years. He is also a member of the Board of Directors of HBM Healthcare Investments.
W. Kent Geer is a former audit partner (retired) with Ernst & Young, LLP. His 37 year career spans an extensive track record in serving numerous public and private companies in a variety of industries including biotechnology, pharmaceuticals and other technology companies. During his tenure, Mr. Geer was the audit practice leader for the Ernst & Young Entrepreneurial Services Group in Raleigh, North Carolina and was the market team leader for the technology industry practice of the Carolinas. Beginning in 2012, Mr. Geer served as the Chairman of the Board of PowerSecure International, Inc. (NYSE:POWR) until the successful sale of the company in May 2016.
Robert Keegan is the former Chief Executive Officer and Chairman of the Board of The Goodyear Tire & Rubber Company, roles that he held until his retirement in 2010. Most recently, he was an operating partner of the San Francisco-based private equity firm Friedman, Fleischer & Lowe. From 1972 to 2000, Mr. Keegan held various marketing, financial and managerial posts at Eastman Kodak, except for a two-year period from 1995 to 1997 when he worked as an Executive Vice President of the Avery Dennison Corporation. Mr. Keegan is Chairman of the Board of Loparex, Inc., serves on the boards of the Fuqua Business School and the Heart Center of Duke University and is a partner of L&K Properties of North Carolina, LLC.
G. Kelly Martin is Chief Executive Officer of Novan, Inc. He served as CEO of Elan, Ireland’s largest indigenous biotech company, from February 2003 until its successful $8.6 Billion sale to Perrigo Company in December 2013. Before joining Elan, Mr. Martin spent more than 20 years at Merrill Lynch & Co., Inc., where he held a broad array of operating and executive responsibilities. Mr. Martin also serves as a non-executive director on a number of public and private company boards and is a co-founder and director of Brandon Point Industries.
Dr. Palmour is a Co-founder, the Chief Technology Officer, Power & RF, and a Vice President of Cree, Inc. Dr. Palmour has authored or co-authored more than 360 publications and is a co-inventor on 65 U.S. patents and 150 corresponding foreign patents. He has been a Program Manager or Principal Investigator on government research contracts to Cree totaling more than $160 million. Having served as a member of the Board of Directors of Cree for fifteen years, Dr. Palmour has extensive experience and expertise in advancing innovation to broad-scale product commercialization.
Machelle Sanders is a seasoned executive with over 29 years of progressive pharmaceutical and biotechnology experience. Ms. Sanders is Secretary of the N.C. Department of Administration, appointed by Governor Roy Cooper. In the private sector, Ms. Sanders was most recently responsible for the pharmaceutical operations and technology operational strategy for Biogen’s multiple sclerosis (MS) franchise (i.e. AVONEX™, PLEGRIDY™, TECFIDERA™, and TYSABRI™). She held the title of vice president of manufacturing and general manager of the company’s largest and most advanced manufacturing facility in Research Triangle Park, North Carolina. Ms. Sanders has also held leadership positions in manufacturing, global quality assurance and quality control at Biogen, Purdue Pharmaceuticals, and Diosynth-Akzo Nobel. She holds a bachelor of science degree in Biochemistry from North Carolina State University and a masters of health administration (MHA) from Pfeiffer University.
Paula Brown Stafford, MPH, is the President and Chief Operating Officer of Novan responsible for the translation of Novan's nitric oxide technology into druggable assets across a range of therapeutic areas. Prior to joining Novan, she served as president of clinical development at Quintiles (now QuintilesIMS), where she was responsible for all Phase I-IV clinical development operations globally, reaching $3 billion in annual revenue. In addition to her role at Novan, Ms. Stafford continues to participate in other professional activities, including serving as a director at Health Decisions, Inc. and adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at The University of North Carolina at Chapel Hill, and also maintains her third-party consulting business. She was named as one of the 10 top women in biotech by FierceBiotech in 2012, recognized as a Distinguished Alumna at UNC Chapel Hill in 2016, and recently designated an NACD Governance Fellow. She holds a Bachelor of Science and a Masters in Public Health, both from The University of North Carolina at Chapel Hill, with her specialization in Biostatistics.
Dr. Sun served as the Chief Executive Officer for Melinta Therapeutics from 2015 to 2017 and as its Executive Vice President from 2013 to 2015. Prior to joining Melinta, Dr. Sun held senior positions at Abbott Laboratories, most recently as Corporate Vice President, Global Pharmaceutical Clinical Development. During his 17-year tenure at Abbott, Dr. Sun led the development and worldwide regulatory approval of the landmark human immunodeficiency virus (HIV) protease inhibitor Kaletra® and oversaw the development and approval of multiple indications for Humira®. From 2001 to 2007, Dr. Sun served on the U.S. Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee, a panel of independent infectious disease experts. After earning an undergraduate degree from Harvard University and a medical degree from New York University School of Medicine, Dr. Sun completed an internship and residency in internal medicine and a fellowship in infectious diseases at the University of California, San Francisco. During his fellowship, Dr. Sun received a National Research Service Award and a Physician Scientist Award from the National Institutes of Health.